Skip to main content
NCBI home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 1996;4(5):258–262. doi: 10.1155/S1064744996000506

Piperacillin/Tazobactam (ZOSYN)

Stephanie M Culver 1,✉, Mark G Martens 1
PMCID: PMC2364504  PMID: 18476104

Full Text

The Full Text of this article is available as a PDF (421.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akova M., Yang Y., Livermore D. M. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases. J Antimicrob Chemother. 1990 Feb;25(2):199–208. doi: 10.1093/jac/25.2.199. [DOI] [PubMed] [Google Scholar]
  2. Baron E. J., Jones R. N. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers. Diagn Microbiol Infect Dis. 1995 Mar;21(3):141–151. doi: 10.1016/0732-8893(95)00018-6. [DOI] [PubMed] [Google Scholar]
  3. Faro S. Infectious disease relations to cesarean section. Obstet Gynecol Clin North Am. 1988 Dec;15(4):685–695. [PubMed] [Google Scholar]
  4. File T. M., Jr, Tan J. S. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections. Eur J Surg Suppl. 1994;(573):51–55. [PubMed] [Google Scholar]
  5. Higashitani F., Hyodo A., Ishida N., Inoue M., Mitsuhashi S. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin. J Antimicrob Chemother. 1990 Apr;25(4):567–574. doi: 10.1093/jac/25.4.567. [DOI] [PubMed] [Google Scholar]
  6. Jones R. N., Pfaller M. A., Fuchs P. C., Aldridge K., Allen S. D., Gerlach E. H. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):489–494. [PubMed] [Google Scholar]
  7. Kinzig M., Sörgel F., Brismar B., Nord C. E. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother. 1992 Sep;36(9):1997–2004. doi: 10.1128/aac.36.9.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lockwood C. J., Costigan K., Ghidini A., Wein R., Chien D., Brown B. L., Alvarez M., Cetrulo C. L. Double-blind; placebo-controlled trial of piperacillin prophylaxis in preterm membrane rupture. Am J Obstet Gynecol. 1993 Oct;169(4):970–976. doi: 10.1016/0002-9378(93)90037-j. [DOI] [PubMed] [Google Scholar]
  9. Marshall S. A., Aldridge K. E., Allen S. D., Fuchs P. C., Gerlach E. H., Jones R. N. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years. Diagn Microbiol Infect Dis. 1995 Mar;21(3):153–168. doi: 10.1016/0732-8893(95)00019-7. [DOI] [PubMed] [Google Scholar]
  10. Sanders W. E., Jr, Sanders C. C. Piperacillin/tazobactam: a critical review of the evolving clinical literature. Clin Infect Dis. 1996 Jan;22(1):107–123. doi: 10.1093/clinids/22.1.107. [DOI] [PubMed] [Google Scholar]
  11. Schoonover L. L., Occhipinti D. J., Rodvold K. A., Danziger L. H. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination. Ann Pharmacother. 1995 May;29(5):501–514. doi: 10.1177/106002809502900510. [DOI] [PubMed] [Google Scholar]
  12. Stobberingh E. E. In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases. Chemotherapy. 1990;36(3):209–214. doi: 10.1159/000238768. [DOI] [PubMed] [Google Scholar]
  13. Sweet R. L., Robbie M. O., Ohm-Smith M., Hadley W. K. Comparative study of piperacillin versus cefoxitin in the treatment of obstetric and gynecologic infections. Am J Obstet Gynecol. 1983 Feb 1;145(3):342–349. doi: 10.1016/0002-9378(83)90722-6. [DOI] [PubMed] [Google Scholar]
  14. Sweet R. L., Roy S., Faro S., O'Brien W. F., Sanfilippo J. S., Seidlin M. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group. Obstet Gynecol. 1994 Feb;83(2):280–286. [PubMed] [Google Scholar]
  15. Sörgel F., Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother. 1993 Jan;31 (Suppl A):39–60. doi: 10.1093/jac/31.suppl_a.39. [DOI] [PubMed] [Google Scholar]
  16. Weber D. A., Sanders C. C. Diverse potential of beta-lactamase inhibitors to induce class I enzymes. Antimicrob Agents Chemother. 1990 Jan;34(1):156–158. doi: 10.1128/aac.34.1.156. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES